Uniphar’s acquisition of the Sam McCauley chain of pharmacies has been approved by the competition regulator subject to some conditions.
The Competition and Consumer Protection Commission (CCPC) sanctioned the deal, valued at an estimated €50 million, that will see Uniphar acquire LXV Remedies (M/22/049), the parent company of 37 pharmacy outlets across Leinster, Munster and Ulster, from investment fund Carlyle Cardinal Ireland and the chain’s founder, Sam McCauley.
The regulator said that, following the conclusion of its phase-one investigation into the deal notified to it last September, and subject to the commitments given by Dublin-listed Uniphar, it had decided that that the proposed acquisition would not substantially lessen competition.
Uniphar has agreed to sell three pharmacies – in Athy, Co Kildare; Navan, Co Meath; and Bunclody, Co Wexford – to satisfy concerns about competition in those counties. The three will be sold as going concerns to an approved buyer and Uniphar will not move to buy any of the three outlets back for an agreed period.
Stealth sackings: why do employers fire staff for minor misdemeanours?
How much of a threat is Donald Trump to the Irish economy?
MenoPal app offers proactive support to women going through menopause
Ezviz RE4 Plus review: Efficient budget robot cleaner but can suffer from wanderlust under the wrong conditions
The CCPC in December blocked a multimillion-euro Uniphar move to acquire pharmacy solutions business NaviCorp on competition grounds, the first time in more than a decade that Irish competition authorities prohibited a transaction.
